The aggressive capital raise via an expanded ATM facility signals that management expects to need significant cash, likely to fund OLC commercialization if approved on June 29. The PDUFA catalyst is binary — approval could temporarily offset dilution concerns, while a CRL would likely accelerate ATM usage. Monitor the June 29 PDUFA date closely; the stock may trade on the approval outcome rather than the dilution overhang in the near term.
Price Chart
Executive Summary
Unicycive Therapeutics filed a universal shelf registration statement on Form S-3 to register up to $150 million in securities, including a dedicated $50 million ATM facility with Guggenheim Securities. The filing comes just 24 days after the company reported a net loss of $12.8 million for Q1 2026 and with a PDUFA date of June 29, 2026 for its lead candidate OLC. The company has been aggressively raising capital via its existing ATM, selling $19.6 million in Q1 2026 and an additional $11.2 million post-quarter, and now seeks to expand its capacity for further dilution.
Key Financial Metrics
Key Facts
- Shelf registration for up to $150 million in securities, including a $50 million ATM facility with Guggenheim Securities.
- Q1 2026 net loss of $12.8 million vs. net income of $0.6 million in Q1 2025, driven by a $4.8 million non-cash warrant liability charge.
- Cash and marketable securities of $54.6 million as of March 31, 2026, up from $41.3 million at year-end 2025 due to $19.6 million in ATM proceeds.
- Post-quarter, sold 1,693,000 shares at $7.34/share for net proceeds of $11.2 million via the existing ATM.
- Accumulated deficit of $140.6 million as of March 31, 2026.
- PDUFA target action date for OLC (oxylanthanum carbonate) NDA resubmission is June 29, 2026.
- Outstanding warrants and convertible preferred stock represent significant potential future dilution — over 20 million additional common shares issuable.
- 27,393,027 shares outstanding as of June 5, 2026.
Financial Impact
Up to $150 million in potential future dilution from the shelf; $50 million ATM alone represents ~25% of current market cap at $7.43/share. Q1 2026 net loss of $12.8 million vs. $0.6 million income in Q1 2025.
Risk Factors
- Massive potential dilution — up to $150M in new securities could be issued, with $50M ATM alone representing ~25% of current market cap.
- PDUFA risk on June 29, 2026 — a second CRL would remove the primary value catalyst and likely trigger accelerated ATM drawdowns.
- Operating losses are accelerating — Q1 2026 operating loss of $8.4M vs. $8.0M in Q1 2025, with no revenue.
- Warrant liability of $21.7M creates balance sheet volatility from non-cash fair value adjustments.
- Significant overhang from convertible preferred stock and warrants — over 20M additional common shares potentially issuable.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001213900-26-065819 |
| Document: ea029178901ex4-3.htm | 0001213900-26-065819 |
| Document: ea029178901ex4-4.htm | 0001213900-26-065819 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | 3 | $4.22 | awaiting T+60 | — | $3.58 (−15.17%) |
Sep 29, 2026 27d ago | 8-K | $4.55 | awaiting T+60 | — | $3.58 (−21.32%) |
Aug 12, 2026 10w ago | 8-K | $5.39 | awaiting T+60 | — | $3.58 (−33.58%) |
Jul 2, 2026 16w ago | 8-K | $5.73 $4.81 | ▼ −16.06% | ▼ −19.06% | $3.58 (−37.52%) |
Jun 22, 2026 18w ago | DEFA14A | $7.87 $4.71 | ▼ −40.15% | ▼ −41.90% | $3.58 (−54.51%) |
Jun 16, 2026 18w ago | EFFECT | $7.17 $5.31 | ▲ +25.94% | ▲ +26.94% | $3.58 (+50.07%) |
Jun 5, 2026 20w ago | S-3 | $6.66 $5.05 | ▲ +24.17% | ▲ +27.23% | $3.58 (+46.25%) |
May 12, 2026 23w ago | 8-K | $8.17 $5.05 | ▼ −38.19% | ▼ −42.57% | $3.58 (−56.18%) |
May 12, 2026 23w ago | Press Release | $8.17 $5.05 | ▲ +38.19% | ▲ +42.57% | $3.58 (+56.18%) |
Apr 6, 2026 29w ago | 8-K | $6.62 $5.28 | ▼ −20.24% | ▼ −33.71% | $3.58 (−45.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers